1. Home
  2. PACK vs CUVL Comparison

PACK vs CUVL Comparison

Compare PACK & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ranpak Holdings Corp

PACK

Ranpak Holdings Corp

N/A

Current Price

$3.18

Market Cap

420.2M

ML Signal

N/A

Logo Clinuvel Pharmaceuticals Limited American Depositary Shares

CUVL

Clinuvel Pharmaceuticals Limited American Depositary Shares

N/A

Current Price

$5.84

Market Cap

374.2M

Sector

Miscellaneous

ML Signal

N/A

Company Overview

Basic Information
Metric
PACK
CUVL
Founded
1972
1999
Country
United States
Australia
Employees
N/A
N/A
Industry
Containers/Packaging
Miscellaneous
Sector
Consumer Discretionary
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
420.2M
374.2M
IPO Year
2017
2004

Fundamental Metrics

Financial Performance
Metric
PACK
CUVL
Price
$3.18
$5.84
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $7.08
N/A
AVG Volume (30 Days)
★ 613.1K
5.1K
Earning Date
10-29-2026
08-27-2026
Dividend Yield
N/A
★ 0.55%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $395,000,000.00
N/A
Revenue This Year
$9.87
$0.47
Revenue Next Year
$9.00
$6.25
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 7.08
N/A
52 Week Low
$3.05
$4.88
52 Week High
$7.81
$8.20

Technical Indicators

Market Signals
Indicator
PACK
CUVL
Relative Strength Index (RSI) 31.50 43.59
Support Level N/A $4.91
Resistance Level $4.40 $5.40
Average True Range (ATR) 0.23 0.25
MACD 0.01 0.03
Stochastic Oscillator 12.77 30.08

Price Performance

Historical Comparison
PACK
CUVL

About PACK Ranpak Holdings Corp

Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.

About CUVL Clinuvel Pharmaceuticals Limited American Depositary Shares

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Share on Social Networks: